Precisemab Biotech is a research-driven biotechnology company pioneering tumor-selective antibody therapeutics through its proprietary Antibody Lock Platform.
Our mission is to advance a new generation of safer and more precise biologics that minimize systemic toxicity while maintaining strong anti-tumor efficacy.
With a growing pipeline of preclinical and clinical-stage programs, Precisemab aims to redefine the therapeutic index of antibody-based medicines and create sustainable value for patients, partners, and investors.
Investor Relations
Precisemab Biotech is a preclinical-stage biotechnology company focused on developing tumor-selective and conditionally activated antibody therapeutics through its proprietary Antibody Lock Technology Platform. This platform is designed to keep antibodies inactive in normal tissues and selectively activated within tumor or disease microenvironments, achieving an optimal balance of precision, safety, and efficacy.
The company is advancing several antibody programs driven by tumor-selective activation, including PSM101, a tumor-activated anti-EGFR antibody, and PSM915, an immune-modulating antibody candidate, while expanding its applications to bispecific antibodies (Lock BsAb) and antibody-drug conjugates (Lock ADC).
Guided by the belief that effective and safe treatments empower patients with the courage to fight illness, Precisemab is redefining how biologics perform in the body and shaping a new generation of intelligent antibody therapies. Our mission extends beyond innovation—we aim to create lasting value for patients, partners, and investors by advancing safer and smarter biologic medicines.
We warmly welcome future partners and investors to connect with us and join our mission in building the next generation of precision antibody therapies.
Partner with Precisemab to unlock the potential of Antibody Lock Technology.
We collaborate with biotechnology and pharmaceutical partners to co-develop tumor-activated antibodies, bispecifics, and ADCs, enabling new therapeutic strategies in oncology and immune modulation.
Our expertise spans from molecular design to preclinical validation, ensuring rapid translation from concept to candidate.
We welcome strategic alliances that leverage our technology platform to create safer, more effective antibody therapeutics for patients worldwide.
Together for Better Treatments
We work with partners to achieve innovative drug solutions for patients.
What Issues We Are Working On
Monoclonal antibodies offer strong therapeutic benefits, yet traditional designs cannot distinguish between diseased and healthy tissues. This lack of selectivity often leads to dose-limiting on-target toxicity, preventing patients from receiving optimal treatment. Many promising antibodies therefore remain constrained by safety concerns rather than efficacy.
How We Solve the Problem
Precisemab’s Universal Antibody Lock enables antibodies to remain inactive in healthy tissues and become activated only within disease-associated microenvironments. This conditional activation platform enhances precision and safety without altering the antibody’s native properties, and it can be broadly applied across autoimmune diseases, oncology, immunotherapy, and antibody drug conjugates.
What Are the Applications
The Antibody Lock technology allows us to improve the safety and performance of existing antibody drugs, revive clinical programs previously halted due to toxicity, and create new therapeutic opportunities by extending the value of antibodies approaching patent expiration. It provides partners with both innovation and differentiation.
Together, We Can Make a Better Future
Precisemab is actively seeking strategic partners to bring safer and more selective antibody therapies to patients. By working together, we aim to translate precision engineering into meaningful clinical benefit and long-term value for all partners.
Our partnering opportunities include
Precisemab Developed Antibody Out-Licensing
Customized Lock-Design Service
Join Us
Building a Healthier Future Together
Our Partners
